STOCK TITAN

[Form 4] Cardio Diagnostics Holdings, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Director Wendy J. Betts reported acquiring 1,559 stock options of Cardio Diagnostics Holdings, Inc. (CDIO) on 09/30/2025. The options have an exercise price of $4.01, are exercisable immediately (09/30/2025) and expire on 09/30/2035. The filing shows these options cover 1,559 underlying shares, and following the reported transaction Ms. Betts beneficially owns 4,002 shares of common stock. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 10/03/2025. The report is a Section 16 disclosure of insider changes in beneficial ownership and contains no additional financial results or contractual terms beyond the option details.

Director Wendy J. Betts ha riportato di aver acquisito 1,559 opzioni su azioni di Cardio Diagnostics Holdings, Inc. (CDIO) il 09/30/2025. Le opzioni hanno un prezzo di esercizio di $4.01, sono esercitabili immediatamente (09/30/2025) e scadono il 09/30/2035. L’atto di deposito mostra che queste opzioni coprono 1,559 azioni sottostanti, e dopo l’operazione riportata la Signora Betts detiene beneficariamente 4,002 azioni ordinarie. Il Form 4 è stato firmato per conto della persona riportante da un procuratore il 10/03/2025. Il rapporto è una divulgazione della Sezione 16 di cambiamenti di proprietà beneficiaria e non contiene ulteriori risultati finanziari o termini contrattuali oltre i dettagli delle opzioni.

La directora Wendy J. Betts informó haber adquirido 1,559 opciones sobre acciones de Cardio Diagnostics Holdings, Inc. (CDIO) el 30/09/2025. Las opciones tienen un precio de ejercicio de $4.01, son ejercitables de inmediato (30/09/2025) y vencen el 30/09/2035. El archivo muestra que estas opciones cubren 1,559 acciones subyacentes y, tras la operación reportada, la Sra. Betts posee beneficiosamente 4,002 acciones comunes. El Form 4 fue firmado en nombre de la persona reportante por un apoderado el 03/10/2025. El informe es una divulgación de la Sección 16 de cambios de propiedad beneficiaria y no contiene otros resultados financieros ni términos contractuales además de los detalles de las opciones.

감독 Wendy J. Betts는 Cardio Diagnostics Holdings, Inc. (CDIO)의 주식 옵션 1,559주를 09/30/2025에 취득했다고 보고했습니다. 옵션의 행사 가격은 $4.01이며 즉시 행사 가능하고 (09/30/2025) 09/30/2035에 만료됩니다. 제출 문서는 이 옵션이 1,559주의 기초 주식을 커버함을 보여주고, 보고된 거래 이후 베츠 씨는 유리하게 4,002주의 보통주를 보유합니다. Form 4는 보고자 대신 대리인이 10/03/2025에 서명했습니다. 이 보고서는 내부자 보유 변화에 대한 Section 16 공개이며 옵션 세부 정보 외에 추가적인 재무 실적이나 계약 조건을 포함하지 않습니다.

La directrice Wendy J. Betts a déclaré avoir acquis 1 559 options d’achat d’actions de Cardio Diagnostics Holdings, Inc. (CDIO) le 30/09/2025. Les options ont un prix d’exercice de $4.01, sont exerçables immédiatement (30/09/2025) et expirent le 30/09/2035. Le dossier indique que ces options couvrent 1 559 actions sous-jacentes et, suite à la transaction rapportée, Mme Betts détient bénéficiairement 4 002 actions ordinaires. Le Form 4 a été signé au nom de la personne rapportante par un mandataire le 03/10/2025. Le rapport est une divulgation de la Section 16 sur les changements de propriété bénéficiaire et ne contient pas d’autres résultats financiers ni de termes contractuels au-delà des détails des options.

Die Direktorin Wendy J. Betts berichtete, am 30.09.2025 insgesamt 1.559 Aktienoptionen von Cardio Diagnostics Holdings, Inc. (CDIO) erworben zu haben. Die Optionen haben einen Ausübungspreis von $4.01, sind sofort ausübbar (30.09.2025) und laufen am 30.09.2035 ab. Die Einreichung zeigt, dass diese Optionen 1.559 zugrunde liegende Aktien abdecken, und nach der gemeldeten Transaktion besitzt Frau Betts vorteilhaft 4.002 Stammaktien. Das Form 4 wurde im Namen der meldepflichtigen Person von einem Bevollmächtigten am 03.10.2025 unterzeichnet. Der Bericht ist eine Section-16-Offenlegung über Insiderveränderungen im beherrschenden Eigentum und enthält keine zusätzlichen finanziellen Ergebnisse oder vertraglichen Bedingungen über die Optionsdetails hinaus.

أعلنت المديرة ويندي ج. بيتس أنها قد اكتسبت 1,559 خياراً للأسهم من Cardio Diagnostics Holdings, Inc. (CDIO) في 30/09/2025. سعر تمارين الخيارات هو $4.01، وقابلة للتنفيذ فوراً (30/09/2025) وتنتهي صلاحيتها في 30/09/2035. يظهر الملف أن هذه الخيارات تغطي 1,559 سهماً أساسياً، وبعد المعاملة المبلغ عنها تملك السيدة بيتس بشكل مستفيد 4,002 سهماً عادياً. تم توقيع النموذج 4 نيابة عن الشخص المبلغ عنه بواسطة وكيل في 03/10/2025. التقرير هو إفصاح القسم 16 عن تغيّرات الملكية المفيدة ولا يحتوي على نتائج مالية إضافية أو شروط تعاقدية بخلاف تفاصيل الخيارات.

董事 Wendy J. Betts09/30/2025 据 Cardio Diagnostics Holdings, Inc. (CDIO) 收购了 1,559 份股票期权。期权行使价为 $4.01,可立即行使 (09/30/2025),并于 09/30/2035 到期。这份备案显示这些期权覆盖 1,559 股基础股票,且据报道交易后 Betts 女士实际拥有 4,002 股普通股。Form 4 由代表报告人之代理人在 10/03/2025 签署。该报告是关于内幕变化的第16条披露,除了期权细节外,不包含其他财务结果或合同条款。

Positive
  • Director acquisition: 1,559 options acquired at $4.01 shows insider participation
  • Immediate exercisability: Options exercisable on 09/30/2025, providing clear vesting/exercise status
Negative
  • None.

Director Wendy J. Betts ha riportato di aver acquisito 1,559 opzioni su azioni di Cardio Diagnostics Holdings, Inc. (CDIO) il 09/30/2025. Le opzioni hanno un prezzo di esercizio di $4.01, sono esercitabili immediatamente (09/30/2025) e scadono il 09/30/2035. L’atto di deposito mostra che queste opzioni coprono 1,559 azioni sottostanti, e dopo l’operazione riportata la Signora Betts detiene beneficariamente 4,002 azioni ordinarie. Il Form 4 è stato firmato per conto della persona riportante da un procuratore il 10/03/2025. Il rapporto è una divulgazione della Sezione 16 di cambiamenti di proprietà beneficiaria e non contiene ulteriori risultati finanziari o termini contrattuali oltre i dettagli delle opzioni.

La directora Wendy J. Betts informó haber adquirido 1,559 opciones sobre acciones de Cardio Diagnostics Holdings, Inc. (CDIO) el 30/09/2025. Las opciones tienen un precio de ejercicio de $4.01, son ejercitables de inmediato (30/09/2025) y vencen el 30/09/2035. El archivo muestra que estas opciones cubren 1,559 acciones subyacentes y, tras la operación reportada, la Sra. Betts posee beneficiosamente 4,002 acciones comunes. El Form 4 fue firmado en nombre de la persona reportante por un apoderado el 03/10/2025. El informe es una divulgación de la Sección 16 de cambios de propiedad beneficiaria y no contiene otros resultados financieros ni términos contractuales además de los detalles de las opciones.

감독 Wendy J. Betts는 Cardio Diagnostics Holdings, Inc. (CDIO)의 주식 옵션 1,559주를 09/30/2025에 취득했다고 보고했습니다. 옵션의 행사 가격은 $4.01이며 즉시 행사 가능하고 (09/30/2025) 09/30/2035에 만료됩니다. 제출 문서는 이 옵션이 1,559주의 기초 주식을 커버함을 보여주고, 보고된 거래 이후 베츠 씨는 유리하게 4,002주의 보통주를 보유합니다. Form 4는 보고자 대신 대리인이 10/03/2025에 서명했습니다. 이 보고서는 내부자 보유 변화에 대한 Section 16 공개이며 옵션 세부 정보 외에 추가적인 재무 실적이나 계약 조건을 포함하지 않습니다.

La directrice Wendy J. Betts a déclaré avoir acquis 1 559 options d’achat d’actions de Cardio Diagnostics Holdings, Inc. (CDIO) le 30/09/2025. Les options ont un prix d’exercice de $4.01, sont exerçables immédiatement (30/09/2025) et expirent le 30/09/2035. Le dossier indique que ces options couvrent 1 559 actions sous-jacentes et, suite à la transaction rapportée, Mme Betts détient bénéficiairement 4 002 actions ordinaires. Le Form 4 a été signé au nom de la personne rapportante par un mandataire le 03/10/2025. Le rapport est une divulgation de la Section 16 sur les changements de propriété bénéficiaire et ne contient pas d’autres résultats financiers ni de termes contractuels au-delà des détails des options.

Die Direktorin Wendy J. Betts berichtete, am 30.09.2025 insgesamt 1.559 Aktienoptionen von Cardio Diagnostics Holdings, Inc. (CDIO) erworben zu haben. Die Optionen haben einen Ausübungspreis von $4.01, sind sofort ausübbar (30.09.2025) und laufen am 30.09.2035 ab. Die Einreichung zeigt, dass diese Optionen 1.559 zugrunde liegende Aktien abdecken, und nach der gemeldeten Transaktion besitzt Frau Betts vorteilhaft 4.002 Stammaktien. Das Form 4 wurde im Namen der meldepflichtigen Person von einem Bevollmächtigten am 03.10.2025 unterzeichnet. Der Bericht ist eine Section-16-Offenlegung über Insiderveränderungen im beherrschenden Eigentum und enthält keine zusätzlichen finanziellen Ergebnisse oder vertraglichen Bedingungen über die Optionsdetails hinaus.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Betts Wendy J

(Last) (First) (Middle)
C/O CARDIO DIAGNOSTICS HOLDINGS INC.
311 W. SUPERIOR ST. SUITE 444

(Street)
CHICAGO IL 60654

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Cardio Diagnostics Holdings, Inc. [ CDIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy) $4.01 09/30/2025 A 1,559 09/30/2025 09/30/2035 Common Stock 1,559 $4.01 4,002 D
Explanation of Responses:
/s/ Elisa Luqman as attorney-in-fact for Wendy Betts 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Cardio Diagnostics (CDIO) director Wendy Betts report?

She reported acquiring 1,559 stock options on 09/30/2025 with an exercise price of $4.01.

How many shares does Wendy Betts beneficially own after the reported transaction?

The Form 4 shows she beneficially owns 4,002 shares following the transaction.

When do the options become exercisable and when do they expire?

The options are exercisable on 09/30/2025 and expire on 09/30/2035.

Who signed the Form 4 and when was it signed?

The Form 4 was signed by Elisa Luqman as attorney-in-fact for Wendy Betts on 10/03/2025.

What is the reporting person’s relationship to CDIO?

The filing identifies Wendy J. Betts as a Director of Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings Inc

NASDAQ:CDIO

CDIO Rankings

CDIO Latest News

CDIO Latest SEC Filings

CDIO Stock Data

7.70M
1.64M
7.16%
4.81%
0.98%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States
CHICAGO